|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WARS |
Gene summary for WARS |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WARS | Gene ID | 7453 |
| Gene name | tryptophanyl-tRNA synthetase 1 | |
| Gene Alias | GAMMA-2 | |
| Cytomap | 14q32.2 | |
| Gene Type | protein-coding | GO ID | GO:0001525 | UniProtAcc | A0A024R6K8 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7453 | WARS | P128T-E | Human | Esophagus | ESCC | 4.12e-24 | 8.57e-01 | 0.1241 |
| 7453 | WARS | P130T-E | Human | Esophagus | ESCC | 9.12e-48 | 1.14e+00 | 0.1676 |
| 7453 | WARS | HCC1_Meng | Human | Liver | HCC | 5.22e-61 | 1.29e-01 | 0.0246 |
| 7453 | WARS | HCC2_Meng | Human | Liver | HCC | 3.43e-08 | 4.19e-02 | 0.0107 |
| 7453 | WARS | HCC2 | Human | Liver | HCC | 1.28e-12 | 4.11e+00 | 0.5341 |
| 7453 | WARS | S014 | Human | Liver | HCC | 8.37e-13 | 4.69e-01 | 0.2254 |
| 7453 | WARS | S015 | Human | Liver | HCC | 1.68e-16 | 8.33e-01 | 0.2375 |
| 7453 | WARS | S016 | Human | Liver | HCC | 5.60e-18 | 7.16e-01 | 0.2243 |
| 7453 | WARS | S027 | Human | Liver | HCC | 4.09e-11 | 2.26e+00 | 0.2446 |
| 7453 | WARS | S028 | Human | Liver | HCC | 1.11e-26 | 1.79e+00 | 0.2503 |
| 7453 | WARS | S029 | Human | Liver | HCC | 1.72e-25 | 2.88e+00 | 0.2581 |
| 7453 | WARS | C04 | Human | Oral cavity | OSCC | 3.47e-29 | 1.48e+00 | 0.2633 |
| 7453 | WARS | C21 | Human | Oral cavity | OSCC | 2.28e-57 | 2.67e+00 | 0.2678 |
| 7453 | WARS | C30 | Human | Oral cavity | OSCC | 4.25e-63 | 5.40e+00 | 0.3055 |
| 7453 | WARS | C38 | Human | Oral cavity | OSCC | 1.33e-04 | 1.11e+00 | 0.172 |
| 7453 | WARS | C43 | Human | Oral cavity | OSCC | 5.21e-20 | 5.74e-01 | 0.1704 |
| 7453 | WARS | C46 | Human | Oral cavity | OSCC | 2.88e-19 | 8.97e-01 | 0.1673 |
| 7453 | WARS | C51 | Human | Oral cavity | OSCC | 3.10e-18 | 1.59e+00 | 0.2674 |
| 7453 | WARS | C57 | Human | Oral cavity | OSCC | 1.69e-27 | 1.42e+00 | 0.1679 |
| 7453 | WARS | C06 | Human | Oral cavity | OSCC | 8.53e-11 | 2.67e+00 | 0.2699 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:014005313 | Esophagus | ESCC | mitochondrial gene expression | 93/8552 | 108/18723 | 1.96e-18 | 2.03e-16 | 93 |
| GO:003254314 | Esophagus | ESCC | mitochondrial translation | 68/8552 | 76/18723 | 1.02e-15 | 6.86e-14 | 68 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00009592 | Esophagus | ESCC | mitochondrial RNA metabolic process | 39/8552 | 49/18723 | 1.20e-06 | 1.49e-05 | 39 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WARS | SNV | Missense_Mutation | novel | c.341N>G | p.Lys114Arg | p.K114R | P23381 | protein_coding | tolerated(0.18) | benign(0.011) | TCGA-LL-A7T0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WARS | insertion | Frame_Shift_Ins | novel | c.836_837insCCCAACTCACCCCTACAAGACTTTTTCCCCCTCAATA | p.Phe280ProfsTer45 | p.F280Pfs*45 | P23381 | protein_coding | TCGA-AO-A12F-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | ||
| WARS | SNV | Missense_Mutation | rs370081524 | c.92N>T | p.Ala31Val | p.A31V | P23381 | protein_coding | tolerated_low_confidence(0.08) | benign(0.02) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WARS | SNV | Missense_Mutation | c.585G>A | p.Met195Ile | p.M195I | P23381 | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-FU-A23L-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| WARS | SNV | Missense_Mutation | rs751453486 | c.1343G>A | p.Arg448Gln | p.R448Q | P23381 | protein_coding | deleterious(0.02) | benign(0.074) | TCGA-HM-A3JJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| WARS | SNV | Missense_Mutation | novel | c.1165N>A | p.Gln389Lys | p.Q389K | P23381 | protein_coding | tolerated(0.99) | benign(0.001) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| WARS | SNV | Missense_Mutation | novel | c.961N>T | p.Arg321Trp | p.R321W | P23381 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| WARS | SNV | Missense_Mutation | novel | c.481N>T | p.Gly161Cys | p.G161C | P23381 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD |
| WARS | SNV | Missense_Mutation | rs370081524 | c.92C>T | p.Ala31Val | p.A31V | P23381 | protein_coding | tolerated_low_confidence(0.08) | benign(0.02) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| WARS | SNV | Missense_Mutation | c.539C>A | p.Thr180Lys | p.T180K | P23381 | protein_coding | deleterious(0) | possibly_damaging(0.812) | TCGA-G4-6626-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |